Tricia Mullins, Bcpa
About Tricia Mullins, Bcpa
Tricia Mullins, BCPA, is the Executive Director, Global Head of Early Patient Engagement and Professional Societies (Ex-China) at BeiGene, with over 20 years of experience in patient engagement and advocacy.
Executive Director at BeiGene
Currently serving as the Executive Director and Global Head of Early Patient Engagement and Professional Societies (Ex-China) at BeiGene. Oversees global initiatives focusing on innovative patient engagement strategies and professional society collaboration to support the clinical drug development journey.
Global Head, Patient Advocacy at Atara Biotherapeutics
Holds a key position as the Global Head of Patient Advocacy at Atara Biotherapeutics. Responsible for leading patient advocacy efforts, fostering collaborations with patient communities, and ensuring that the patient's voice is integrated into the company's initiatives.
President at RARE PAC, LLC
Currently working as the President of RARE PAC (Patient Advocacy Consulting/ TMC), located in Encinitas, CA. Leads commercial access and engagement strategies, focusing on rare diseases and patient advocacy. Brings extensive experience in building and leading patient advocacy programs.
Co-Chair at THE NEUROMUSCULAR DISEASE FOUNDATION
Acts as Co-Chair of the Board of Directors at the Neuromuscular Disease Foundation, specifically collaborating on gene therapy initiatives. Supports strategic planning and provides guidance on patient engagement to enhance research and treatment development.
Extensive Career in Biotechnology and Patient Advocacy
Boasts over 20 years of experience in the biotech industry with a specialization in patient engagement and advocacy. Has held pivotal roles at various organizations including Halozyme Therapeutics, Horizon Pharma, Esperion, Global Genes, AbbVie, Novelion Therapeutics, Dyax, UCB, Cubist Pharmaceuticals, Actelion, Elan, and Bayer. Known for designing advocacy programs, strategic planning, and integrating patient perspectives into clinical drug development.